GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP-1 receptor agonists (GLP-1RAs) have rapidly increased as a treatment for type 2 diabetes mellitus and obesity due to their effectiveness in improving glycemic control, promoting weight loss, and offering cardiovascular benefits [1].